» Articles » PMID: 12600206

Structure, Function, and Aggregation of the Zinc-free Form of the P53 DNA Binding Domain

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2003 Feb 26
PMID 12600206
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 DNA binding domain (DBD) contains a single bound zinc ion that is essential for activity. Zinc remains bound to wild-type DBD at temperatures below 30 degrees C; however, it rapidly dissociates at physiological temperature. The resulting zinc-free protein (apoDBD) is folded and stable. NMR spectra reveal that the DNA binding surface is altered in the absence of Zn(2+). Fluorescence anisotropy studies show that Zn(2+) removal abolishes site-specific DNA binding activity, although full nonspecific DNA binding affinity is retained. Surprisingly, the majority of tumorigenic mutations that destabilize DBD do not appreciably destabilize apoDBD. The R175H mutation instead substantially accelerates the rate of Zn(2+) loss. A considerable fraction of cellular p53 may therefore exist in the folded zinc-free form, especially when tumorigenic mutations are present. ApoDBD appears to promote aggregation of zinc-bound DBD via a nucleation-growth process. These data provide an explanation for the dominant negative phenotype exhibited by many mutations. Through a combination of induced p53 aggregation and diminished site-specific DNA binding activity, Zn(2+) loss may represent a significant inactivation pathway for p53 in the cell.

Citing Articles

Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications.

Mustafa M, Ahmad R, Tantry I, Ahmad W, Siddiqui S, Alam M Cells. 2024; 13(22).

PMID: 39594587 PMC: 11592877. DOI: 10.3390/cells13221838.


Bioinformatic Characterization of the Functional and Structural Effect of Single Nucleotide Mutations in Patients with High-Grade Glioma.

Velez Gomez S, Martinez Garro J, Ortiz Gomez L, Salazar Florez J, Monroy F, Pelaez Sanchez R Biomedicines. 2024; 12(10).

PMID: 39457600 PMC: 11505048. DOI: 10.3390/biomedicines12102287.


Navigating the complexity of p53-DNA binding: implications for cancer therapy.

Thayer K, Stetson S, Caballero F, Chiu C, Han I Biophys Rev. 2024; 16(4):479-496.

PMID: 39309126 PMC: 11415564. DOI: 10.1007/s12551-024-01207-4.


Multiscale simulations reveal the driving forces of p53C phase separation accelerated by oncogenic mutations.

Yu Y, Liu Q, Zeng J, Tan Y, Tang Y, Wei G Chem Sci. 2024; 15(32):12806-12818.

PMID: 39148776 PMC: 11323318. DOI: 10.1039/d4sc03645j.


Cellular zinc status alters chromatin accessibility and binding of p53 to DNA.

Ocampo D, Damon L, Sanford L, Holtzen S, Jones T, Allen M Life Sci Alliance. 2024; 7(9).

PMID: 38969365 PMC: 11231577. DOI: 10.26508/lsa.202402638.